Adding anti-clotting drugs to stroke care ineffective, clinical trial finds
Clinical trial finds adding anti-clotting drugs to stroke care ineffective; medications did not improve patients’ outcomes, as indicated in The New England Journal of Medicine.
Highlighted Terms
Related News
A clinical trial led by Opeolu Adeoye, MD, at Washington University School of Medicine in St. Louis found that adding anti-coagulant drugs to thrombolysis treatment did not improve outcomes for stroke patients, as published in The New England Journal of Medicine on Sept. 4.
WashU Medicine's MOST trial found anti-clotting drugs argatroban and eptifibatide failed to improve stroke outcomes, leading to higher disability and mortality rates.
A clinical trial led by Dr. Opeolu Adeoye found that adding anti-coagulant drugs argatroban or eptifibatide to thrombolysis treatment did not improve stroke outcomes, with both drugs linked to higher disability and mortality rates. The study, published in The New England Journal of Medicine, concludes that neither drug helps prevent further clots, closing a chapter on their potential use but informing future advances in stroke treatment.
Clinical trial finds adding anti-clotting drugs to stroke care ineffective; medications did not improve patients’ outcomes, as indicated in The New England Journal of Medicine.